Xintela receives Notice of Allowance from USPTO for the treatment of brain tumorsLund, Sweden, January 7, 2021 - Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintela's patent application 15/550,837 in the USA protects the use of the target molecule integrin 101 for antibody based treatment of tumors of the CNS, including glioblastoma. Xintela has now received a Notice of Allowance which means that the USPTO intends to grant the patent after completion of certain formal steps. Once granted, the patent can be kept in force until 2036. The corresponding European patent application was recently granted by the European Patent Office (EPO).
"We are very pleased with this Notice of Allowance which adds significant value to our oncology business and strengthens Xintela's patent protection on the important US market," says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela has previously reported that the company's ADC (Antibody-Drug Conjugate) antibodies have the capability to kill glioblastoma cells, both in cell based studies and in an animal model. The results have been published in the journal Cancers (2019, Vol. 11, p. 587). Additionally, in December 2019, Xintela announced that the company's function-blocking antibodies have demonstrated an inhibitory effect on glioblastoma tumor growth in a preclinical study.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 08:30 CET on the 7th of January, 2021.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela is an Advanced Therapy company developing innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].
The following documents can be retrieved from beQuoted
2021-01-07-Patent-godkannande-USPTO ENG.pdf
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 